Human Clinical Study: Assessment of Zicam Cold Remedy RapidMelts
- Conditions
- to shorten the duration, reduce the number and decrease the sevity of common cold symptoms in otherwise healthy human adult volunteers
- Registration Number
- EUCTR2005-004641-34-GB
- Lead Sponsor
- Matrixx Initiatives Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Onset of common cold symptoms within 24 hours preceding pre-enrolment screening.Male and female volunteers 18 years of age and above.In good general health other than the common cold.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Cold symptoms for more than 24 hours at time of enrolment.History of perennial allergic rhinitis, asthma or any other chronic respiratory disease.Prior history of adverse reaction to zinc, calcium or any of the inactive ingredients of Zicam RapidMelts tablets.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Shorten the duration of common cold symptoms;Secondary Objective: Reduce the number of common cold symptoms2. Decrease the severity of common cold symptoms<br>Decrease the severity of common cold symptoms;Primary end point(s): End of common cold symptoms
- Secondary Outcome Measures
Name Time Method